Modafinil ADHD Marketing Plans Include DTC After First Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon's promotional plans for the attention deficit/hyperactivity disorder treatment modafinil (formerly Attenace) include direct-to-consumer ads after the product's first year on the market
You may also be interested in...
Johnson & Johnson To Co-Promote Cephalon's ADHD Treatment Modafinil
Deal allows J&J to opt out if its own attention deficit/hyperactivity disorder therapy Concerta loses exclusivity.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.